Humana — Apr 29, 2026 release

The FY 2026 Adjusted EPS guidance anticipates a year-over-year decline as a result of the Star Ratings headwind for Bonus Year (BY) 2026, net of mitigation. 2 Diluted earnings per share (a) FY 2026  Guidance FY 2025 GAAP at least $8.36 $9.84  Amortization associated with identifiable intangibles 0.30   0.42  Put/call valuation adjustments associated with the company's non-consolidating minority interest investments (b) (0.28) 4.25  Value creation initiatives (b) 0.81   3.72  Impact of exit of employer group commercial medical products business (b) —   (0.52) Settlement of certain litigation expenses (b) —   0.13  Loss on sale of business (b) —   0.55  Impairment charges (b) —   2.09  Cumulative net tax impact (0.19) (3.34) Adjusted (non-GAAP) – FY 2026 projected (b); FY 2025 reported at least $9.00 $17.14  Refer to the "Footnotes" section included herein for further explanation of disclosures for Adjusted (non-GAAP) financial measures, as well as additional reconciliations. Detailed Press Release Humana’s full earnings press release, including the statistical pages, has been posted to the company’s Investor Relations site and may be accessed at https://humana.gcs-web.com/ or via a current report on Form 8-K filed by the company with the Securities and Exchange Commission this morning (available at www.sec.gov or on the company’s website). Conference Call Humana will host a live question-and-answer session for an